Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is primarily metabolized via glucuronidation by the uridine 5′‐diphospho‐glucuronosyltransferase (UGT) isoform UGT1A9. This noncompartmental meta‐analysis of ertugliflozin pharmacokinetics evaluated the relationship between ertugliflozin exp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2021-09, Vol.61 (9), p.1220-1231
Hauptverfasser:	Marshall, Jean‐Claude, Liang, Yali, Sahasrabudhe, Vaishali, Tensfeldt, Thomas, Fediuk, Daryl J., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas Kumar, Wood, Linda S., Sweeney, Kevin
Format:	Artikel
Sprache:	eng
Schlagworte:	Area Under Curve Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics Clinical Trials, Phase I as Topic Dose-Response Relationship, Drug ertugliflozin Gene polymorphism Genotype Genotype & phenotype Glucuronosyltransferase Glucuronosyltransferase - genetics Humans Meta-analysis Metabolic Clearance Rate Models, Biological Na+/glucose cotransporter pharmacogenetics Pharmacogenomics Pharmacokinetics Polymorphism, Genetic Sodium-Glucose Transporter 2 Inhibitors - administration & dosage Sodium-Glucose Transporter 2 Inhibitors - pharmacokinetics UDP-Glucuronosyltransferase 1A9 - genetics UDP‐glucuronosyltransferase 1A9 Uridine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!